Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE, /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa ...
Oncology Nurse Advisor

In HR+, HER2+ Early Breast Cancer, Aromatase Inhibitor Improves 10-Year Outcomes Compared to SERM

In this analysis of the phase 3 ALLTO trial, researchers explored 10-year outcomes of HR+, HER2+ early breast cancer patients who received either an aromatase inhibitor or a selective estrogen ...

Athira Pharma, Inc.: Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA"

Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high ...

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”

Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it ...
Oncology Nurse Advisor

San Antonio Breast Cancer Symposium

Oncology Nurse Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that the U.S. Food and Drug Administration ...
Seeking Alpha

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs ...
Business Insider

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing ...
Hosted on MSN

Watch teak wood stain transform bare wood instantly

I'm showcasing the stunning results you can achieve using a teak stain on wood. In this video, I respond to a viewer's comment about teak by demonstrating how beautifully this color enhances and ...
Mena FN

SERM Market Outlook 2034: Clinical Trials, FDA Approvals, Market Size, Therapies, Companies By Delveinsight

(MENAFN - GetNews) "SERM Market"The Selective Estrogen Receptor Modulators (SERMs) market is anticipated to witness significant expansion in the coming years, fueled by the increasing prevalence of ...
Finanznachrichten

DelveInsight Business Research, LLP: SERM Market Shows Promising Growth Trajectory During the Study Period (2020-2034) Owing to the Rising Demand in Oncology and Women's Health ...

The SERMs market is projected to experience substantial growth in the near future, driven by a rising incidence of cancer diagnoses, growing awareness about SERMs, and a surge in the number of SERMs ...